ORM-5029
ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2) -targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab. ORM-5029 exhibits robust efficacy across 14 HER2-positive breast cancer cell lines, with IC50 values ranging from 0.3 to 14.4 nM.ORM-5029 demonstrates anti-tumor activity in the BT474 xenograft model. ORM-5029 can be used for study of breast cancer[1][2][3].
Product Specifications
UNSPSC
12352211
Target
Antibody-Drug Conjugates (ADCs)
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/orm-5029.html
Purity
99.60
Smiles
[R]O[M5029]
References & Citations
[1]Sara A. Hurvitz, et al. A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors. Journal of Clinical Oncology. Volume 41, Number 16_suppl. May 31, 2023.|[2]James Palacino, et al. ORM-5029: A first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer.|[3]Tao Y, et al. Molecular glue meets antibody: next-generation antibody-drug conjugates. Trends Pharmacol Sci. 2025 Jun;46 (6) :520-534.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS460252-01 0.1 mg
Mouse anti Alpha Fetoprotein (AFP) Monoclonal Antibody
Sign In for Pricing
View Details